Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.14
+6.1%
$0.73
$0.28
$2.45
$424.75M1.136.86 million shs2.88 million shs
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$18.87
-0.9%
$19.49
$8.10
$29.82
$337.16M1.26209,397 shs36,059 shs
Verastem, Inc. stock logo
VSTM
Verastem
$4.72
-1.8%
$6.22
$2.10
$9.10
$259.64M0.711.28 million shs622,062 shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$11.36
+8.3%
$10.19
$5.83
$26.25
$475.19MN/A187,564 shs111,158 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
+16.74%+16.82%+43.60%+116.03%-33.13%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
+3.37%+2.09%-12.86%+17.10%+133.91%
Verastem, Inc. stock logo
VSTM
Verastem
+2.12%-0.82%-21.28%+6.42%+72.40%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
+5.22%+2.64%-12.00%+54.72%+1,048,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.7285 of 5 stars
3.23.00.00.02.22.50.6
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.4243 of 5 stars
3.20.00.00.00.01.73.1
Verastem, Inc. stock logo
VSTM
Verastem
2.5689 of 5 stars
3.53.00.00.00.72.50.6
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.2134 of 5 stars
3.50.00.00.00.60.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.40
Hold$3.67223.05% Upside
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.40
Hold$36.4092.95% Upside
Verastem, Inc. stock logo
VSTM
Verastem
3.00
Buy$13.38183.13% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
3.00
Buy$36.67222.77% Upside

Current Analyst Ratings Breakdown

Latest LXRX, ZBIO, RIGL, and VSTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Verastem, Inc. stock logo
VSTM
Verastem
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00
6/24/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
5/16/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/15/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$35.00
5/9/2025
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $14.00
5/7/2025
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.00
4/10/2025
Verastem, Inc. stock logo
VSTM
Verastem
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$31.08M13.20N/AN/A$0.40 per share2.84
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$203.08M1.66$1.11 per share17.07$0.19 per share99.29
Verastem, Inc. stock logo
VSTM
Verastem
$10K25,958.38N/AN/A($0.65) per share-7.27
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$5M95.04N/AN/A$7.48 per share1.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%7/30/2025 (Estimated)
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$17.49M$2.079.1117.97N/A18.31%-655.26%24.47%8/5/2025 (Estimated)
Verastem, Inc. stock logo
VSTM
Verastem
-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$156.99M-$3.55N/AN/AN/AN/AN/A8/21/2025 (Estimated)

Latest LXRX, ZBIO, RIGL, and VSTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.07N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$1.42N/AN/AN/A$64.58 millionN/A
5/15/2025Q1 2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million
5/13/2025Q1 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million
5/13/2025Q1 2025
Verastem, Inc. stock logo
VSTM
Verastem
-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A
5/6/2025Q1 2025
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$0.14$0.63+$0.49$0.63$43.87 million$53.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.48
2.22
2.22
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.42
2.20
2.13
Verastem, Inc. stock logo
VSTM
Verastem
N/A
3.50
3.50
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A
6.47
6.47

Institutional Ownership

CompanyInstitutional Ownership
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
66.23%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
13.90%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
9.48%
Verastem, Inc. stock logo
VSTM
Verastem
2.10%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140361.49 million311.25 millionOptionable
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
16017.87 million16.18 millionOptionable
Verastem, Inc. stock logo
VSTM
Verastem
5054.95 million53.80 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A41.83 million34.93 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.14 +0.07 (+6.07%)
As of 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Rigel Pharmaceuticals stock logo

Rigel Pharmaceuticals NASDAQ:RIGL

$18.86 -0.18 (-0.92%)
As of 12:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Verastem stock logo

Verastem NASDAQ:VSTM

$4.72 -0.09 (-1.79%)
As of 12:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$11.36 +0.87 (+8.29%)
As of 12:14 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.